STOCK TITAN
  1. Home
  2. News
  3. XRTX

XORTX Therapeutics Inc. - XRTX STOCK NEWS

Welcome to our dedicated page for XORTX Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on XORTX Therapeutics stock.

XORTX Therapeutics Inc. (NASDAQ: XRTX) is a bio-pharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating progressive kidney diseases worldwide. Headquartered in Calgary, Canada, XORTX focuses on addressing serious health conditions related to aberrant purine and uric acid metabolism, including diabetic nephropathy, polycystic kidney disease (PKD), and complications arising from diabetes and cardiovascular diseases.

The company has two lead programs targeting progressive kidney disease due to diabetes and PKD. Additionally, XORTX is actively involved in the development of uric acid-lowering agents to treat conditions like hypertension, insulin resistance, metabolic syndrome, and diabetes. Their pipeline includes xanthine oxidase inhibitors that show potential in managing diabetic nephropathy.

One of XORTX's strategic milestones is its alliance with Teijin Pharma Limited for the development of TMX-049, a promising xanthine oxidoreductase inhibitor. Another significant partnership is with the Icahn School of Medicine, focusing on studying acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc. is at the clinical-stage of biotechnology, aiming to identify, develop, and potentially commercialize therapies that can slow or reverse the progression of chronic kidney diseases. Their focus includes addressing the immediate needs of individuals facing acute kidney injury (AKI) due to respiratory virus infections and exploring other opportunities where their intellectual property can mitigate various health issues.

News

XORTX Announces US ATM Offering

Rhea-AI Summary
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) announces an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the Company to offer and sell common shares without par value with an aggregate offering price of up to US$3,701,931. The Company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.74%
Tags
none
-
News

XORTX Meets Nasdaq Continued Listing Requirements

Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) has received a letter of compliance from Nasdaq regarding the minimum bid price requirement, leading to the curing of the deficiency. The company's common shares are now trading at or above US$1.00 per share for at least 10 consecutive trading days, resulting in the receipt of the compliance letter from Nasdaq. This development ensures that trading of the company's common shares on Nasdaq will continue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
-
News

XORTX Clarifies Timing for Share Consolidation

Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the consolidation of its common shares on a 1:9 basis, with trading on the TSXV and Nasdaq to begin today. The consolidation is part of the Company's focus on developing therapies for progressive kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-88.89%
Tags
none
News

XORTX Announces Share Consolidation

Rhea-AI Summary
XORTX Therapeutics Inc. (XRTX) announces the approval of consolidating its common shares on a one post-consolidation Share for every nine pre-consolidation Shares basis, effective November 9, 2023. The number of issued and outstanding Shares will be reduced from 17,989,687 to approximately 1,998,854. The Shares will continue to trade on the TSXV and the Nasdaq under the symbol XRTX on a post-Consolidation basis, under a new CUSIP number – 98420Q306.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
-
News

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023

Rhea-AI Summary
XORTX Therapeutics Inc. announces new research findings on the role of uric acid in polycystic kidney disease and the potential of their proprietary formulation of oxypurinol as a treatment option. The studies show that moderate soluble uric acid can accelerate kidney expansion rate and worsen kidney function, and xanthine oxidase inhibition may be predictive of therapeutic benefit. The company plans to advance their formulation of oxypurinol in a clinical registration trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
-
News

XORTX Announces Results of Special Meeting of Shareholders

Rhea-AI Summary
XORTX Therapeutics announces shareholder approval of share consolidation resolution to maintain NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
none
News

XORTX Announces Date for Rescheduled Special Meeting of Shareholders

Rhea-AI Summary
XORTX Therapeutics reschedules special meeting of shareholders to consider share consolidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.81%
Tags
none
-
News

XORTX Announces Rescheduling of Special Meeting of Shareholders

Rhea-AI Summary
XORTX Therapeutics cancels special meeting of shareholders and plans to reschedule. The meeting was called to consider a share consolidation to regain compliance with NASDAQ listing requirements. The cancellation is due to a significant change in shareholder base and potential misleading proxy solicitation activities. XORTX believes a NASDAQ listing is important for liquidity and funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.65%
Tags
none
-
News

XORTX Calls Special Meeting of Shareholders

Rhea-AI Summary
XORTX Therapeutics Inc. announces a special meeting of shareholders to consider a share consolidation for compliance with NASDAQ listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.4%
Tags
none
News

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023

Rhea-AI Summary
XORTX Therapeutics announces acceptance of abstract on the effect of lowering uric acid on PKD in mice, to be presented at ASN meeting. Results suggest uric acid lowering is necessary for therapeutic benefit. Positive for XORTX's innovative therapies for kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of XORTX Therapeutics (XRTX)?

The current stock price of XORTX Therapeutics (XRTX) is $1.444 as of November 1, 2024.

What is the market cap of XORTX Therapeutics (XRTX)?

The market cap of XORTX Therapeutics (XRTX) is approximately 4.6M.

What is XORTX Therapeutics Inc.?

XORTX Therapeutics Inc. is a bio-pharmaceutical company focused on developing and commercializing therapies to treat progressive kidney diseases worldwide.

What are the main diseases XORTX targets?

XORTX targets progressive kidney diseases such as diabetic nephropathy, polycystic kidney disease, and complications from diabetes and cardiovascular diseases.

Where is XORTX Therapeutics headquartered?

XORTX Therapeutics Inc. is headquartered in Calgary, Canada.

What is TMX-049?

TMX-049 is a xanthine oxidoreductase inhibitor being developed by XORTX in collaboration with Teijin Pharma Limited.

Who are XORTX's strategic partners?

XORTX has strategic partnerships with Teijin Pharma Limited and the Icahn School of Medicine.

What stage is XORTX Therapeutics in?

XORTX Therapeutics Inc. is a clinical-stage biotechnology company.

What health issues does XORTX aim to address?

XORTX aims to address health issues related to aberrant purine and uric acid metabolism, such as diabetic nephropathy, hypertension, insulin resistance, and metabolic syndrome.

What is the focus of XORTX's pipeline?

The focus of XORTX's pipeline includes developing therapies to slow or reverse chronic kidney diseases and addressing acute kidney injury due to respiratory virus infections.

What are xanthine oxidase inhibitors?

Xanthine oxidase inhibitors are a class of drugs that reduce uric acid production and are being developed by XORTX to manage conditions like diabetic nephropathy.

How does XORTX contribute to COVID-19 research?

XORTX collaborates with the Icahn School of Medicine to study acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

Stock XRTX logo
XORTX Therapeutics Inc.

Nasdaq:XRTX

XRTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

XRTX Stock Data

4.61M
3.22M
3.35%
6.37%
0.01%
Biotechnology
Healthcare
Link
United States of America
Alberta Beach